🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Comparison of olaparib vs. physician's choice of single agent standard of c...
Status
Completed
Location
Research Site
Start Date
2015-02-06
Trial ID
NCT02282020
Treatments Being Tested
The aim of this adaptive Phase 3 trial is to show a statistically significa...
Status
Completed
Location
Compassionate Cancer Care Medical Group, Inc
Start Date
2018-10-16
Trial ID
NCT03126435
Treatments Being Tested
This is a phase 3 study. All subjects are patients with unresectable locall...
Status
Active Not Recruiting
Location
Harbin Medical University Cancer Hospital
Start Date
2024-10-20
Trial ID
NCT06591520
Treatments Being Tested
Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) ...
Status
Terminated
Location
Highlands Oncology Group
Start Date
2022-12-14
Trial ID
NCT05493501
Study is aimed at evaluating the activity of Trabectedin (arm A) in advance...
Status
Recruiting
Location
Azienda Ospedaliera S. Orsola-Malpighi
Start Date
2021-10-29
Trial ID
NCT04383119
Treatments Being Tested
The purpose of this study is to determine the maximum tolerated dose (MTD) ...
Status
Terminated
Location
University of Arizona Cancer Center, Tucson
Start Date
2017-03-05
Trial ID
NCT02954406
Treatments Being Tested
A first in human study to evaluate the safety and preliminary antitumor act...
Status
Recruiting
Location
The Angeles Clinic and Research Institute - West Los Angeles Office
Start Date
2025-03-31
Trial ID
NCT06917079
The primary objective of the study is to determine the maximum tolerated do...
Status
Completed
Location
Alabama Oncology
Start Date
2013-03-29
Trial ID
NCT01803282
A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Adv...
Status
Unknown
Location
Fudan University Shanghai Cancer Center
Start Date
2022-02
Trial ID
NCT05257122
Treatments Being Tested
This open-label, multicenter, Phase I, dose-escalation study will evaluate ...
Status
Completed
Location
Yale Cancer Center
Start Date
2012-03-23
Trial ID
NCT01564251
Treatments Being Tested